458 related articles for article (PubMed ID: 16227410)
1. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells.
Safaei R; Larson BJ; Cheng TC; Gibson MA; Otani S; Naerdemann W; Howell SB
Mol Cancer Ther; 2005 Oct; 4(10):1595-604. PubMed ID: 16227410
[TBL] [Abstract][Full Text] [Related]
2. Administration of isothiocyanate (E-4IB) and cisplatin leads to altered signalling and lysosomal export in human ovarian carcinoma sensitive- and cisplatin-resistant cells.
Duraj J; Hunakova L; Bodo J; Jakubikova J; Chovancova J; Sedlak J
Neoplasma; 2009; 56(3):208-14. PubMed ID: 19309223
[TBL] [Abstract][Full Text] [Related]
3. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
4. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.
Safaei R; Katano K; Larson BJ; Samimi G; Holzer AK; Naerdemann W; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):756-67. PubMed ID: 15701866
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
Katano K; Kondo A; Safaei R; Holzer A; Samimi G; Mishima M; Kuo YM; Rochdi M; Howell SB
Cancer Res; 2002 Nov; 62(22):6559-65. PubMed ID: 12438251
[TBL] [Abstract][Full Text] [Related]
6. Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function.
Ma L; Xu Y; Su J; Yu H; Kang J; Li H; Li X; Xie Q; Yu C; Sun L; Li Y
Int J Oncol; 2015 Nov; 47(5):1890-900. PubMed ID: 26397057
[TBL] [Abstract][Full Text] [Related]
7. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
Ma J; Maliepaard M; Kolker HJ; Verweij J; Schellens JH
Cancer Chemother Pharmacol; 1998; 41(3):186-92. PubMed ID: 9443634
[TBL] [Abstract][Full Text] [Related]
8. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
9. Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells.
Gagliardi S; Mitruccio M; Di Corato R; Romano R; Aloisi A; Rinaldi R; Alifano P; Guerra F; Bucci C
Cell Commun Signal; 2024 Mar; 22(1):165. PubMed ID: 38448982
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
Brooks SE; Korbut TT; Dupuis NP; Holden SA; Teicher BA
Cancer Chemother Pharmacol; 1995; 36(5):431-8. PubMed ID: 7634385
[TBL] [Abstract][Full Text] [Related]
11. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
12. Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway.
Zhang Y; Tao L; Fan LX; Huang K; Luo HM; Ge H; Wang X; Wang Q
Mol Med Rep; 2019 Mar; 19(3):2287-2296. PubMed ID: 30664215
[TBL] [Abstract][Full Text] [Related]
13. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
Solár P; Sytkowski AJ
Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
[TBL] [Abstract][Full Text] [Related]
14. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
15. Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells.
Basu A; Weixel KM
Int J Cancer; 1995 Aug; 62(4):457-60. PubMed ID: 7635571
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.
Mansouri A; Zhang Q; Ridgway LD; Tian L; Claret FX
Oncol Res; 2003; 13(6-10):399-404. PubMed ID: 12725530
[TBL] [Abstract][Full Text] [Related]
17. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis.
Yamamoto K; Okamoto A; Isonishi S; Ochiai K; Ohtake Y
Biochem Biophys Res Commun; 2001 Feb; 280(4):1148-54. PubMed ID: 11162647
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
19. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
20. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha.
Mizutani Y; Bonavida B
Cancer; 1993 Aug; 72(3):809-18. PubMed ID: 8334635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
